Table of Contents
ISRN Pharmacology
Volume 2012 (2012), Article ID 417515, 8 pages
http://dx.doi.org/10.5402/2012/417515
Research Article

Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its Fragment in an Immunocompetent Mouse Model

1Tumor Immunology Direction, Molecular Immunology Institute, Center of Molecular Immunology, 216 Street, 15th Avenue, Atabey, Siboney, Playa, P.O. Box 16040, 11600 Havana, Cuba
2Departments of Pharmacology and Toxicology, Institute of Pharmacy and Foods, University of Havana, 11600 Havana, Cuba
3Radiobiology Laboratory, Center for Radiation Protection and Hygiene, 11600 Havana, Cuba

Received 8 October 2012; Accepted 23 October 2012

Academic Editors: K. Cimanga, G. Gervasini, T. Kumai, and T. B. Vree

Copyright © 2012 Ailem Rabasa Capote et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Reichert and E. Dhimolea, “The future of antibodies as cancer drugs,” Drug Discovery Today, vol. 17, no. 17-18, pp. 954–963, 2012. View at Publisher · View at Google Scholar
  2. T. Crombet, M. Osorio, T. Cruz et al., “Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1646–1654, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. M. O. Rodríguez, T. C. Rivero, R. D. C. Bahi et al., “Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck,” Cancer Biology and Therapy, vol. 9, no. 5, pp. 343–349, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. T. C. Ramos, J. Figueredo, M. Catala et al., “Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial,” Cancer Biology and Therapy, vol. 5, no. 4, pp. 375–379, 2006. View at Google Scholar · View at Scopus
  5. G. Saurez, R. Cabanas, M. Zaldivar et al., “Clinical experience with nimotuzumab in Cuban pediatric patients with brain tumors, 2005 to 2007,” MEDICC Review, vol. 11, no. 3, pp. 27–33, 2009. View at Google Scholar · View at Scopus
  6. M. Ramos-Suzarte, P. Lorenzo-Luaces, N. G. Lazo et al., “Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy,” Cancer Biology & Therapy, vol. 13, no. 8, pp. 600–605, 2012. View at Publisher · View at Google Scholar
  7. G. Bebb, C. Smith, S. Rorke et al., “Phase i clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 4, pp. 837–845, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Massimino, U. Bode, V. Biassoni, and G. Fleischhack, “Nimotuzumab for pediatric diffuse intrinsic pontine gliomas,” Expert Opinion on Biological Therapy, vol. 11, no. 2, pp. 247–256, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Strumberg, B. Schultheis, M. E. Scheulen et al., “Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer,” Investigational New Drugs, pp. 1–6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Perez, E. Moreno, G. Garrido, and T. Crombet, “EGFR-targeting as a biological therapy: understanding Nimotuzumab's clinical effects,” Cancers, vol. 3, no. 2, pp. 2014–2031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Peipp, M. Dechant, and T. Valerius, “Effector mechanisms of therapeutic antibodies against ErbB receptors,” Current Opinion in Immunology, vol. 20, no. 4, pp. 436–443, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Martinelli, R. De Palma, M. Orditura, F. De Vita, and F. Ciardiello, “Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy,” Clinical and Experimental Immunology, vol. 158, no. 1, pp. 1–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. López-Albaitero and R. L. Ferris, “Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer,” Archives of Otolaryngology, vol. 133, no. 12, pp. 1277–1281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Zhang, M. Gordon, A. M. Schultheis et al., “FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single-agent cetuximab,” Journal of Clinical Oncology, vol. 25, no. 24, pp. 3712–3718, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. López-Albaitero, S. C. Lee, S. Morgan et al., “Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells,” Cancer Immunology, vol. 58, no. 11, pp. 1855–1864, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Schneider-Merck, J. J. Van Lammerts Bueren, S. Berger et al., “Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage,” Journal of Immunology, vol. 184, no. 1, pp. 512–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. P. V. Beum, D. A. Mack, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor, “Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes,” Journal of Immunology, vol. 181, no. 11, pp. 8120–8132, 2009. View at Google Scholar · View at Scopus
  19. S. C. Lee, R. M. Srivastava, A. López-Albaitero, S. Ferrone, and R. L. Ferris, “Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity,” Immunologic Research, vol. 50, no. 2-3, pp. 248–254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Garrido, B. Sanchez, H. M. Rodriguez, P. Lorenzano, D. Alonso, and L. E. Fernandez, “7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies,” Hybridoma and Hybridomics, vol. 23, no. 3, pp. 168–175, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Garrido, P. Lorenzano, B. Sánchez et al., “T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies,” Cancer Immunology, vol. 56, no. 11, pp. 1701–1710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Garrido, A. Rabasa, B. Sanchez et al., “Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody,” Journal of Immunology, vol. 187, no. 10, pp. 4954–4966, 2011. View at Publisher · View at Google Scholar
  23. U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970. View at Publisher · View at Google Scholar · View at Scopus
  24. P. J. Fraker and J. C. Speck Jr, “Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril,” Biochemical and Biophysical Research Communications, vol. 80, no. 4, pp. 849–857, 1978. View at Google Scholar · View at Scopus
  25. B. S. Ramírez, E. S. Pestana, G. G. Hidalgo et al., “Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant,” International Journal of Cancer, vol. 119, no. 9, pp. 2190–2199, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. N. H. G. Holford and L. B. Sheiner, “Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models,” Clinical Pharmacokinetics, vol. 6, no. 6, pp. 429–453, 1981. View at Google Scholar · View at Scopus
  27. R. L. Ferris, E. M. Jaffee, and S. Ferrone, “Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape,” Journal of Clinical Oncology, vol. 28, no. 28, pp. 4390–4399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Abès, E. Gélizé, W. H. Fridman, and J. L. Teillaud, “Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response,” Blood, vol. 116, no. 6, pp. 926–934, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Park, Z. Jiang, E. D. Mortenson et al., “The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity,” Cancer Cell, vol. 18, no. 2, pp. 160–170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. Z. Fan, H. Masui, I. Altas, and J. Mendelsohn, “Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies,” Cancer Research, vol. 53, no. 18, pp. 4322–4328, 1993. View at Google Scholar · View at Scopus
  31. D. G. Covell, J. Barbet, and O. D. Holton, “Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice,” Cancer Research, vol. 46, no. 8, pp. 3969–3978, 1986. View at Google Scholar · View at Scopus
  32. C. I. Spiridon, S. Guinn, and E. S. Vitetta, “A comparison of the Min vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies,” Clinical Cancer Research, vol. 10, no. 10, pp. 3542–3551, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Rong, Y. Y. Xiao, F. Y. Dao, Y. Z. Chang, L. G. Pei, and D. Z. Fan, “Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against hantaan virus in healthy volunteers,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 12, pp. 5055–5059, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Puchalski, U. Prabhakar, Q. Jiao, B. Berns, and H. M. Davis, “Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma,” Clinical Cancer Research, vol. 16, no. 5, pp. 1652–1661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Miyake, O. Sawada, M. Kakinoki et al., “Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes,” Investigative Ophthalmology and Visual Science, vol. 51, no. 3, pp. 1606–1608, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Eisenbach, N. Hollander, and L. Greenfeld, “The differential expression of H-2K versus H-2D antigens, distinguishing high- metastatic from low- metastatic clones, is correlated with the immunogenic properties of the tumor cells,” International Journal of Cancer, vol. 34, no. 4, pp. 567–573, 1984. View at Google Scholar · View at Scopus
  37. N. Iznaga Escobar, A. Morales Morales, J. Ducongé, I. Caballero Torres, E. Fernández, and J. A. Gómez, “Pharmacokinetics, biodistribution and dosimetry of 99mTc labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats,” Nuclear Medicine and Biology, vol. 25, no. 1, pp. 17–23, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Crombet, L. Torres, E. Neninger et al., “Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer,” Journal of Immunotherapy, vol. 26, no. 2, pp. 139–148, 2003. View at Publisher · View at Google Scholar · View at Scopus